Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Rev. méd. (La Paz) ; 3(1): 267-70, ene.-mar. 1996. tab
Article in Spanish | LILACS | ID: lil-196506

ABSTRACT

Determinamos la acción de los cambios hormonales, progesterona y estrogeno sobre la hematopoyesis, hemostasia, coagulacion y fibrinolisis, en mujeres nativas de la altura. Se estudio 50 casos, con se respectiva ficha clinica, antes y despues de ciclo menstrual. Se correlacionaron factores geneticos (Grupos, sanguineos: A, B, O). Los sujetos del grupo O y AB, mostraron disminucion significativa de sus reticulocitos (p<0.001). En cambio, los del grupo A y B, aumentaron el numero de estas celulas (p<0.001). Ademas en el grupo sanguineo O, se observo que hacen uso de las reservas de Fe (Protoporfirina), a diferencia de los otros grupos. Referente a la hemostasia, el estudio cuantitativo y cualitativo (numeracion, agragacion y fragilidad capilar), mostraron una disminucion significativa (p<0.05 - p<0.001). En la coagulacion se observo una disminucion significativa en cuanto a la actividad protrombinica y del tiempo de tromboplastina parcial, (p<0.005 y 0.0001). Esto expliacria los sangrados menstruales prolongados y abundantes. Finalmente, la fibrinolisis tuvo valores superiores a 3 horas, en relacion a os valores normales (12 hrs. 30 min). De este trabajo concluimos, que los factores geneticos influyen en la Eritropoyesis, la Hemostasia, Coagulación y Fribrinolisis, en los sujetos de la altura, lo que nos permitira continuar estos estudios, referentes a la Eritrocitosis de nuestro medio.


Subject(s)
Humans , Female , Adolescent , Adult , Partial Thromboplastin Time , Blood Platelets/cytology , Blood Platelets/physiology , Thromboplastin/physiology , Hormones/biosynthesis , Hormones/metabolism , Reference Values , Hemoglobin A/physiology , Menstrual Cycle/physiology , Blood Coagulation Factors/physiology , Blood Group Antigens/physiology , Hematocrit/trends , Data Collection/trends
2.
Arch. med. res ; 27(1): 15-8, 1996. tab
Article in English | LILACS | ID: lil-200284

ABSTRACT

In this study, cimetidine was used to treat patients with hemophilia A and inhibitors to factor VIII who presented with acute hemorrhages (Group A) and those without hemorrahges (Group B). The dose of cimetidine was 15 mg/kg/day. Group A consisted of five patients with inhibitors between 156 and > 10,000 Bethesda Units (BU), all with serious hemorrhagic problems. The control of hemorrhaging was effective in 100 per cent of these patients, although inhibitor levels remained high (25-380 BU). Group B consisted of seven patients who did not have hemorrhages, whose inhibitor levels were 41-358 BU. Five of these patients no longer had anamnestic responses to Factor VIII after several months of treatment with cimetidine. No difference in the response to cimetidine was seen between HIV positive and HIV negative patients. The results suggest that cimetidine is useful to suppress inhibitores to Factor VIII in patients with hemophilia A


Subject(s)
Adolescent , Adult , Humans , Male , Female , Antiviral Agents , Cimetidine/therapeutic use , Factor IX/physiology , Factor VIII/antagonists & inhibitors , Hemophilia A/therapy , Hemorrhage/physiopathology , Interleukin-2/physiology , Ranitidine/therapeutic use , Thromboplastin/physiology
SELECTION OF CITATIONS
SEARCH DETAIL